Cytokinetics inc (CYTK)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Research and development, milestone, grant and other revenues, net

-

-

-

-

-

-

-

-

-

-

40,899

41,051

46,792

44,236

24,730

18,743

14,891

14,740

3,404

8,138

12,334

17,566

18,302

16,036

12,286

7,547

4,675

2,931

3,231

3,382

2,881

2,563

2,216

1,946

1,294

0

0

0

-

Total revenues

22,229

26,868

31,033

35,619

34,697

31,501

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development revenues from related parties, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,170

-

26,197

24,331

21,664

19,538

3,992

2,636

2,356

2,019

2,398

2,797

3,329

4,177

3,251

3,282

2,841

2,054

2,343

1,811

0

0

0

License revenues from related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,269

-

8,787

4,655

1,623

0

0

0

0

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Total revenues

-

-

-

-

-

-

-

-

-

-

46,523

99,390

102,139

106,407

83,027

31,925

32,665

28,658

40,659

42,129

43,375

46,940

49,531

44,585

37,806

30,648

8,483

5,728

6,560

7,559

6,132

5,845

5,057

4,000

3,637

2,672

0

0

0

Operating expenses:
Research and development

84,318

86,125

91,818

92,980

90,545

89,135

91,359

94,915

93,142

90,296

82,820

75,738

65,652

59,897

54,371

48,063

50,976

46,398

41,928

41,791

40,892

44,426

49,471

51,496

52,106

49,450

45,484

40,837

36,732

35,643

34,384

34,477

36,748

37,182

38,130

39,475

0

0

0

General and administrative

42,622

39,610

35,834

33,245

31,455

31,282

34,732

37,225

37,617

36,468

32,885

30,445

29,097

27,823

26,677

24,736

22,141

19,667

18,696

17,413

17,376

17,268

16,803

16,445

15,717

15,092

14,813

14,169

13,007

12,429

11,478

11,691

13,310

13,590

14,139

14,315

0

0

0

Total operating expenses

126,940

125,735

127,652

126,225

122,000

120,417

126,091

132,140

130,759

126,764

115,705

106,183

94,749

87,720

81,048

72,799

73,117

66,065

60,624

59,204

58,268

61,694

66,274

67,941

67,823

64,542

60,297

55,004

49,724

48,016

46,998

47,306

51,209

51,964

52,269

53,790

0

0

0

Restructuring reversals

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-56

-56

0

0

-

0

-

-

-

-

Operating loss

-104,711

-98,867

-96,619

-90,606

-87,303

-88,916

-103,985

-114,495

-116,276

-113,396

-69,182

-6,793

7,390

18,687

1,979

-40,874

-40,452

-37,407

-19,965

-17,075

-14,893

-14,754

-16,743

-23,356

-30,017

-33,894

-51,814

-49,276

-43,164

-40,457

-40,866

-41,461

-46,152

-47,964

-48,632

-51,118

0

0

0

Interest expense

9,530

6,623

5,061

4,583

4,104

3,797

3,311

3,250

3,134

3,016

3,047

2,955

2,880

2,698

1,984

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to the sale of future royalties

21,607

20,737

19,945

19,183

18,457

17,767

17,076

16,423

15,802

13,980

9,930

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income, net

4,117

4,535

4,105

4,408

4,490

4,191

4,066

3,522

3,008

2,602

2,011

1,343

838

464

340

268

199

174

136

124

119

108

185

181

175

177

111

117

103

87

74

74

76

104

132

113

0

0

0

Net (loss) income before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-41,084

-

-19,829

-16,951

-14,774

-14,646

-16,558

-23,175

-29,842

-33,717

-51,703

-49,159

-43,061

-40,370

-40,792

-41,387

-46,076

-47,860

-48,500

-51,005

0

0

0

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

0

0

0

0

0

0

0

0

0

0

0

-

-

-

-

-

0

-

-

0

-

Net loss

-131,731

-121,692

-117,520

-109,964

-105,374

-106,289

-120,306

-130,646

-132,204

-127,790

-80,148

-14,429

3,041

16,453

67

-42,144

-41,084

-37,501

-19,829

-16,951

-14,774

-14,646

-16,558

-23,175

-29,842

-33,717

-51,703

-49,159

-43,061

-40,370

-40,792

-41,387

-46,076

-47,860

-48,324

-50,829

0

0

0

Net (loss) income per share basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.84

-

-

-

-0.23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income per share diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.77

-

-

-

-0.23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average number of shares used in computing net (loss) income per share basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39,926

-

-

-

38,752

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average number of shares used in computing net (loss) income per share diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43,217

-

-

-

38,752

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend related to beneficial conversion feature of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

-

-

Net loss allocable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-41,677

-42,099

-42,694

-48,933

-50,717

-51,181

-53,686

0

0

0

Net loss per share — basic and diluted

-0.66

-0.51

-0.50

-0.56

-0.54

-0.48

-0.40

-0.51

-0.56

-0.77

-0.60

-0.60

-0.62

-

-

-0.29

-0.31

-

-

-0.27

-0.23

-

-0.16

-0.23

-0.27

0.30

-0.43

-0.58

-0.53

-0.96

-0.45

-0.76

-0.13

-3.74

-0.15

-0.23

-0.18

-0.19

-0.21

Weighted-average number of shares used in computing net loss per share — basic and diluted

59

113,957

58,640

57,648

54

54,699

54,626

54,293

54,062

54,101

53,719

48,218

41,578

-

-

39,666

39,592

-

-

38,725

38,675

-

36,609

36,443

32,985

29,922

29,395

25,773

24,010

-39,552

22,360

13,538

76,082

-

72,280

71,151

-

-

-

Other comprehensive income:
Unrealized gain on available-for-sale securities, net

1,007

179

272

311

117

157

21

536

497

206

174

-315

-164

-12

237

216

161

153

-9

0

-18

-11

5

13

3

-11

0

0

0

-

-

-

-

-

-

-

-

-

-

Weighted-average number of shares used in computing net loss per common share - basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

66,911

64,434

63,815

Comprehensive loss

-130,724

-121,513

-117,248

-109,653

-105,257

-106,132

-120,285

-130,110

-131,707

-127,584

-79,974

-14,744

2,877

16,441

304

-41,928

-40,923

-37,348

-19,838

-16,951

-14,792

-14,657

-16,553

-23,162

-29,839

-33,728

-51,697

-49,158

-43,049

-40,355

-40,787

-41,403

-46,087

-47,853

0

0

0

-

-

Research and Development Revenues [Member]
Total revenues

22,229

26,868

31,033

33,704

31,247

26,368

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License Revenues [Member]
Total revenues

-

-

0

1,915

-

5,133

7,226

5,629

9,036

8,799

59,739

61,371

0

-

0

0

-

-

-

-

-

9,836

8,975

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-